Primary Antimicrobial Resistance among Helicobacter pylori Isolated in the Republic of Tatarstan in the 2008–2013 | CMAC

Primary Antimicrobial Resistance among Helicobacter pylori Isolated in the Republic of Tatarstan in the 2008–2013

Clinical Microbiology and Antimicrobial Chemotherapy. 2016; 18(2):146-151

​ Pozdeev O.K., Morozova L.G., Pozdeeva A.O., Valeeva Yu.V., Gulyaev P.E.
H pylori antimicrobial resistance disk diffusion method
Section
Antimicrobial Resistance
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2016; 18(2):146-151

Abstract

This study was aimed to determine isolation rate of H. pylori from gastric mucosal biopsies in 869 patients with chronic gastritis and gastric peptic ulcers in Republic of Tatarstan during the 2008–2013. A total of 45.5% of gastric biopsy samples were positive for H. pylori. Antimicrobial susceptibility testing for H. pylori was performed by disk diffusion method. Over the study period, H. pylori isolated from patients in the both populations were susceptible to clarithromycin, amoxicillin, ciprofloxacin, and tetracycline. In 2008 and 2013, clarithromycin resistance among isolates from patients with chronic gastritis was 3.8% and 4.7%, respectively. In contrast, the only 57.4% and 37% isolates were susceptible to metronidazole. In 2008 and 2013, clarithromycin resistance among H. pylori isolated from patients with gastric peptic ulcer was 5.3% and 8.4%, respectively; metronidazole resistance was 30.3% and 24.6%, respectively

Pozdeev O.K.

Kazan State Medical Academy, Kazan, Russia
Kazan State Medical University, Kazan, Russia

Morozova L.G.

Kazan State Medical Academy, Kazan, Russia

Pozdeeva A.O.

Kazan State Medical Academy, Kazan, Russia

Valeeva Yu.V.

Kazan State Medical University, Kazan, Russia

Pavel E. Gulyaev

Kazan State Medical University, Kazan, Russia

  • 1. van Amsterdam K., van Vliet A.H., Kusters J.G., van der Ende A. Of microbe and man: determinants of Helicobacter pylori-related diseases. FEMS Microbiol Rev 2006; 30:131-56.
  • 2. Ford A.C., Axon A.T.R. Epidemiology of Helicobacter infection and public health implications. Helicobacter 2010; 15:1-6.
  • 3. Щербаков П.Л. Эпидемиология инфекции H.pylori. Helicobacter pylori: революция в гастроэнтерологии. Ивашкин В.Т., Мегро Ф., Лапина Т.Л. - М.: «Триада-Х»; 1999. с. 14-20.
  • 4. Решетников О.В., Курилович С.А., Кротов С.А., Кротова В.А. Мониторинг инфекции, вызванной Helicobacter pylori, в Новосибирске. Журнал микробиологии, эпидемиологии и иммунобиологии 2008; 1:99- 100.
  • 5. Kuipers E.J. Helicobacter pylori and the risk and management of associated diseases: gastritis, ulcer disease, atrophic gastritis and gastric cancer. Aliment Pharmacol Ther 1997; 11(1):71-88.
  • 6. Marshall B. Helicobacter pylori: 20 years on. Clin Med 2002; 2:147-52.
  • 7. Hussain S.A., Hamid S. Helicobacter pylori in humans: Where are we now? Adv Biomed Res 2014; 3:63.
  • 8. Mégraud F., Occhialini A., Doermann H.P. Resistance of Helicobacter pylori to macrolides and nitroimidazole compounds. The current situation. J Physiol Pharmacol 1997; 48(4):25-38.
  • 9. O’Connor A., Taneike I., Nami A., et al. Helicobacter pylori resistance rates for levofloxacin, tetracycline and rifabutin among Irish isolates at a reference centre. Ir J Med Sci 2013; 182:693-5.
  • 10. Ierardi E., Giorgio F., Losurdo G., Di Leo A., Principi M. How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography? World J Gastroenterol 2013; 19:8168-80.
  • 11. Старостин Б.Д., Петрутик А.В. Экспресс-метод диагностики инфицированности Campylobacter pylori желудка и двенадцатиперстной кишки. Клиническая медицина 1989; 67:50-2.
  • 12. Osato M.S. Antimicrobial susceptibility testing for Helicobacter pylori: sensitivity test results and their clinical relevance. Current Pharmaceutical Design 2000; 6:1545-55.
  • 13. Alarcón T., Domingo D., López-Brea M. Discrepancies between E-test and agar dilution methods for testing metronidazole susceptibility of Helicobacter pylori. J Clin Microbiol 1998; 36:1165-6.
  • 14. McNulty C., Owen R., Tompkins D., et al. Helicobacter pylori susceptibility testing by disc diffusion. J Antimicrob Chemother 2002; 49:601-9.
  • 15. Кудрявцева Л.В., Исаков В.А., Иваников И.О. и др. Резистентность H.pylori к метронидазолу, кларитромицину и амоксициллину в Москве, СанктПетербурге и Абакане в 2001 г. Педиатрия 2002; (2, приложение): 61-3.
  • 16. Кудрявцева Л.В. Биологические свойства Helicobacter pylori. Альманах клинической медицины 2006; XIV:39-46.
  • 17. Исаева Г.Ш., Поздеев О.К., Муфер К. Чувствительность клинических изолятов Helicobacter pylori к антибактериальным препаратам. Клин микробиол антимикроб химиотер 2005; 7 (прил. 1):30-1.
  • 18. Smith M.A., Edwards D.I. The influence of microaerophilia and anaerobiosis on metronidazole uptake in Helicobacter pylori. J Antimicrob Chemother 1995; 36:453-61.
  • 19. Abdi Y.M., Young K.A., Rampton D.S., et al. Comparison of the effects of anaerobic and micro-aerophilic incubation on resistance of Helicobacter pylori to metronidazole. J Med Microbiol 1999; 48:407-10.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared